The TCR Australia Series has announced its 2025 calendar, which will include three races on the support programme at ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

The establishment of TCR Arabia's new Yanbu branch marks a significant milestone in the company's expansion strategy. The new location extends TCR Arabia's ability to serve high-profile projects ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and ...

The OPTIMELTTM TCR technology is also compatible with a range of fuels ... Linde also delivers state-of-the-art gas processing solutions to support customer expansion, efficiency improvements and ...

TCR-based therapy genetically modifies natural ... been gearing up to prepare clients for new challenges, following the expansion of their CDMO platform more than two years ago.

6,7 (5) The T cell receptor (TCR) is a protein complex that recognizes different peptides and triggers T cell activation. A TCR genetically engineered to bind specific peptide-HLA complexes can ...

and strategic expansion of existing patents across additional geographies. With over 29 unique patent families worldwide, Medigene safeguards its proprietary TCR and End-to-End Platform ...